Soluble TGF-beta Receptor Isoform for Cartilage Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis and related conditions, such as osteophyte formation and bone remodeling, are inadequate due to the limitations of existing TGF-β signaling modulation, particularly in regulating osteoblast and osteoclast activity and cartilage homeostasis.
Innovation Solution
A soluble isoform of the TGF-beta II receptor (TβRII-SE) lacking a transmembrane domain, which acts as a TGF-β1 agonist, is developed, comprising a specific amino acid sequence, and is used in the form of polynucleotides, vectors, peptides, and antibodies to modulate TGF-β signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a dominant negative TβRII receptor is used to inhibit TGF-β signaling, then osteoarthritis progression is attenuated and cartilage degradation is reduced, but bone remodeling is disrupted and skeletal degeneration occurs
Solution Approach 1:
The patent applies local quality by creating a truncated TβRII isoform that selectively targets specific TGF-β signaling pathways in cartilage tissue while preserving normal bone remodeling functions. The isoform lacks the transmembrane domain and intracellular signaling regions, making it a soluble decoy receptor that binds TGF-β locally in the cartilage microenvironment without triggering the harmful downstream effects seen with dominant negative mutants in bone tissue.
Solution Approach 2:
The patent segments the TβRII receptor into different functional domains, retaining only the extracellular ligand-binding portion (amino acids 1-320) while removing the transmembrane and intracellular domains. This segmentation creates a soluble isoform that can neutralize TGF-β in the extracellular space of cartilage without interfering with membrane-bound receptor signaling in osteoblasts and osteoclasts, thus avoiding skeletal degeneration.
2Quantity of substance
If high concentrations of TGF-β1 are present in subchondral bone, then osteophyte formation is promoted, but cartilage homeostasis is disrupted leading to osteoarthritis
Solution Approach 1:
The patent introduces the soluble TβRII-SE isoform as an intermediary molecule that mediates the interaction between TGF-β1 and its receptors. This soluble isoform acts as a decoy that binds excess TGF-β1 in the cartilage matrix, preventing it from overactivating membrane-bound receptors and disrupting cartilage homeostasis, while allowing physiological TGF-β signaling to continue in subchondral bone for osteophyte formation.
3Reliability
If TGF-β signaling is completely blocked to treat osteoarthritis, then cartilage degradation is reduced, but bone remodeling and osteoblast activity are inhibited
Solution Approach 1:
Instead of using a dominant negative receptor that blocks TGF-β signaling from the inside (inversion of normal signaling), the patent employs a soluble isoform that binds TGF-β extracellularly. This inverted approach allows selective modulation: the soluble TβRII-SE can be concentrated in cartilage tissue where it neutralizes pathogenic TGF-β levels, while leaving bone remodeling processes intact since they occur in a different tissue compartment with different receptor expression patterns.
Data Source
AI summary
An isoform of the TGF beta receptor II comprising a sequence of about of 80 amino acids and lacking a transmembrane domain. The isoform comprises the amino acid sequence set forth in SEQ ID No. 12. The isoform may have the amino acid sequence set forth in SEQ ID No. 2 or sequences having at least 85% sequence identity to the sequence set forth in SEQ ID No. 2. A fusion peptide is provided comprising an isoform of the TGF beta II receptor fused to a ligand, wherein a vector comprising the fusion peptide is used to treat cancer and/or hepatic fibrosis. An antibody binding the soluble isoform of the TGF beta II receptor is provided. The antibody binds the amino acid sequence shown in SEQ ID No. 12 and is used in in vitro methods.